Macfarlanes has advised Charterhouse Capital Partners on the tax aspects of its acquisition of Phastar. Phastar is a fast growing, specialist biometrics clinical research organisation (CRO)…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
